Medicamen Biotech has scheduled its 33rd Annual General Meeting for September 26, 2026. The event will be conducted through Video Conferencing or Other Audio-Visual Means in compliance with Ministry of Corporate Affairs circulars.

The Board of Directors has recommended a dividend of Re.1.00 per equity share of face value ₹10 each. If approved by members, the payout will be credited within 30 days to shareholders on record as of September 19, 2026.

Voting and Logistics

Remote e-voting will commence on September 23, 2026, at 9:00 am and conclude on September 25, 2026, at 5:00 pm. The facility is provided by MUFG Intime India Private Limited. Members who have not cast their votes remotely may vote electronically during the meeting.

Mr. Manoj Kumar Jain, a practicing company secretary, has been appointed as the scrutinizer for the e-voting process. The scrutinizer’s report will be submitted within two working days of the meeting’s conclusion.

Record Date and Access

The register of members will remain closed from September 19, 2026, to determine eligibility for voting and dividend distribution. The Integrated Annual Report for FY25-26 and the AGM notice are available on the company website and stock exchange portals.

Medicamen Biotech Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 to the stock exchanges. The filing, dated September 3, 2026, discloses key operational and financial metrics for the period ending March 31, 2026.

The company reported a total turnover of ₹1,788.46 crore and a profit after tax of ₹94.09 crore. The report also details the company’s sustainability initiatives, governance structures, and compliance with the National Guidelines on Responsible Business Conduct (NGRBC).

Financial Overview

The BRSR filing provides a snapshot of the company’s financial performance for FY26. Alongside the revenue figure, the report discloses the paid-up capital and corporate social responsibility (CSR) spending.

Regarding CSR obligations under Section 135 of the Companies Act, 2013, the company was required to spend ₹31.33 lakh. It incurred ₹25.20 lakh during the year on education and health projects. An unspent amount of ₹6.13 lakh, not related to any ongoing project, is to be transferred to the fund specified in Schedule VII of the Act.

Operational Highlights

Medicamen Biotech operates three manufacturing facilities in India: one in Bhiwadi, Rajasthan, and two units in Haridwar, Uttarakhand. The company serves markets across more than 35 countries, with approximately 80% of its sales generated from international markets. Its product portfolio includes formulations for Oncology, Cardiovascular, Diabetic, and Hypertension treatments, as well as Nutraceuticals.

The company has two subsidiaries: OPAL Pharmaceuticals Pty Ltd in Australia (wholly owned) and Medicamen Life Sciences Private Limited (60% stake). Shivalik Rasayan Limited holds a 40.46% stake in Medicamen Biotech as its holding company.

Governance and Compliance

The report identifies Rahul Bishnoi, Chairman, as the director responsible for implementing business responsibility policies. The Board of Directors, supported by the Stakeholders' Relationship Committee, oversees sustainability strategy and ESG initiatives.

During FY26, the company paid a penalty of ₹7,080 to the National Stock Exchange of India Limited for non-compliance with Regulation 31 of the SEBI Listing Regulations regarding the delay in filing the Shareholding Pattern. No other fines, penalties, or disciplinary actions related to bribery or corruption were reported.

What the Numbers Show

The data reveals a significant concentration in export revenue, with international markets contributing roughly four-fifths of the total turnover. This heavy reliance on overseas sales suggests that the company’s financial performance is closely tied to global regulatory approvals and currency dynamics across its 35+ served countries. Additionally, the rise in related-party purchases to 11.86% from 5.57% in the previous year indicates a growing dependency on specific supply chain partners.